Gate2Brain, a Technology Keybox of BBB-Shuttle Peptides

Gate2Brain

G2B therapeutic-peptide shuttle conjugates are new chemical entities, permeable, non-antigenic, stable, receptor-specific, soluble, non-invasive, and cost-effective products that can cross biological barriers (such as the blood-brain barrier).

Unique properties conferred by
Gate2Brain technology

  • 1

    Ability to penetrate barriers. Our peptides cross biological barriers, such as the blood-brain barrier, to bring therapeutic cargoes to their targets.

    1

Gate2Brain
Gate2Brain

  • 2

    Non-antigenicity. Our proprietary peptides are not immunogenic, minimizing the likelihood of immune reactions against G2B therapeutic-peptide shuttle conjugates.

  • 3

    Protease resistance. Our proprietary peptides bear chemical modifications that increase their half-life up to days, maximizing the area-under-the-curve of G2B therapeutic-peptide shuttle conjugates at their biological targets.

    3

Gate2Brain
Gate2Brain

  • 4

    Receptor specificity. Our proprietary peptides cross biological barriers through receptor-mediated transcytosis.

  • 5

    Water solubility. Our proprietary peptides improve the solubility of practically insoluble small molecule cargoes, making them suitable for human administration.

    5

Gate2Brain
Gate2Brain

  • 6

    Non-invasiveness. Our technology allows the administration of therapeutic cargoes by conventional administration routes.

  • 7

    Cost-effectiveness. Our therapeutic-peptide shuttle conjugates can be produced using low cost and easily scalable processes.

    7

Gate2Brain

Gate2Brain, a Technology Keybox of BBB-Shuttle Peptides

G2B therapeutic-peptide shuttle conjugates are new chemical entities, permeable, non-antigenic, stable, receptor-specific, soluble, non-invasive, and cost-effective products that can cross biological barriers (such as the blood-brain barrier).

Gate2Brain

Unique properties conferred by
Gate2Brain technology

  • 1

    Ability to penetrate barriers. Our peptides cross biological barriers, such as the blood-brain barrier, to bring therapeutic cargoes to their targets.

Gate2Brain

  • 2

    Non-antigenicity. Our proprietary peptides are not immunogenic, minimizing the likelihood of immune reactions against G2B therapeutic-peptide shuttle conjugates.

Gate2Brain

  • 3

    Protease resistance. Our proprietary peptides bear chemical modifications that increase their half-life up to days, maximizing the area-under-the-curve of G2B therapeutic-peptide shuttle conjugates at their biological targets.

Gate2Brain

  • 4

    Receptor specificity. Our proprietary peptides cross biological barriers through receptor-mediated transcytosis.

Gate2Brain

  • 5

    Water solubility. Our proprietary peptides improve the solubility of practically insoluble small molecule cargoes, making them suitable for human administration.

Gate2Brain

  • 6

    Non-invasiveness. Our technology allows the administration of therapeutic cargoes by conventional administration routes.

Gate2Brain

  • 7

    Cost-effectiveness. Our therapeutic-peptide shuttle conjugates can be produced using low cost and easily scalable processes.

Gate2Brain

Scientific Publications

At Gate2Brain, we strongly believe in advancing drug delivery technologies through rigorous scientific research. Our work is grounded in evidence-based innovation, ensuring the development of effective and cutting-edge solutions.

In this section, we showcase our peer-reviewed publications that validate and demonstrate the effectiveness of our peptide-based platform. These studies provide scientific evidence of our technology’s potential and its applications across various therapeutic areas.

New Trends in Brain Shuttle Peptides

2025, by Roger Prades, Meritxell Teixidó and Benjamí Oller-Salvia

A Site-Specific MiniAp4−Trastuzumab Conjugate Prevents Brain Metastasis

2025 , by Mariam Masmudi-Martín, Benjamí Oller-Salvia, María Perea, Meritxell Teixidó, Manuel Valiente, Ernest Giralt and Macarena Sánchez-Navarro

Amphiphilic Polymeric Nanoparticles Modified with Protease-Resistant Peptide Shuttle for the Delivery of SN-38 in Diffuse Intrinsic Pontine Glioma

2021, by Alexandra Bukchin, Macarena Sanchez-Navarro, Adam Carrera, Claudia Resa-Pares, Helena Castillo-Ecija, Leire Balaguer-Lluna, Meritxell Teixidó, Nagore G. Olaciregui, Ernest Giralt, Angel M. Carcaboso and Alejandro Sosnik
Gate2Brain

Gate2Brain is a biotech company focused on the development of therapeutics that efficiently cross biological barriers such as the blood-brain barrier. We use a radically innovative peptide-based patented technology.

Where to find us

Barcelona Scientific Park
Baldiri Reixac, 4-8, Torre I
08028 Barcelona, Spain
info@gate2brain.com

Social